相似文献
1
Sphingolipids and Lipoproteins in Health and Metabolic Disorders.
Trends Endocrinol Metab. 2017 Jul;28(7):506-518. doi: 10.1016/j.tem.2017.03.005. Epub 2017 Apr 24.
2
Molecular Mechanisms of Sphingolipid Transport on Plasma Lipoproteins.
Adv Exp Med Biol. 2022;1372:57-65. doi: 10.1007/978-981-19-0394-6_5.
3
Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism.
Endocr Rev. 2008 Jun;29(4):381-402. doi: 10.1210/er.2007-0025. Epub 2008 May 1.
4
Sphingolipids: players in the pathology of metabolic disease.
Trends Endocrinol Metab. 2009 Jan;20(1):34-42. doi: 10.1016/j.tem.2008.09.004. Epub 2008 Nov 13.
5
A ceramide-centric view of insulin resistance.
Cell Metab. 2012 May 2;15(5):585-94. doi: 10.1016/j.cmet.2012.04.002.
6
Regulation of Sphingolipid Metabolism by MicroRNAs: A Potential Approach to Alleviate Atherosclerosis.
Diseases. 2018 Sep 17;6(3):82. doi: 10.3390/diseases6030082.
7
Sphingolipids in metabolic disease: The good, the bad, and the unknown.
Cell Metab. 2021 Jul 6;33(7):1293-1306. doi: 10.1016/j.cmet.2021.06.006.
8
Ceramides - Lipotoxic Inducers of Metabolic Disorders.
Trends Endocrinol Metab. 2015 Oct;26(10):538-550. doi: 10.1016/j.tem.2015.07.006.
9
Sphingolipids and phospholipids in insulin resistance and related metabolic disorders.
Nat Rev Endocrinol. 2017 Feb;13(2):79-91. doi: 10.1038/nrendo.2016.169. Epub 2016 Oct 21.
10
Microsomal Triglyceride Transfer Protein Transfers and Determines Plasma Concentrations of Ceramide and Sphingomyelin but Not Glycosylceramide.
J Biol Chem. 2015 Oct 23;290(43):25863-75. doi: 10.1074/jbc.M115.659110. Epub 2015 Sep 8.
引用本文的文献
1
Integratomic investigation to assess the liver lipidomic and antiinflammatory activity of lupin protein hydrolysate.
NPJ Sci Food. 2025 Jul 28;9(1):154. doi: 10.1038/s41538-025-00515-7.
2
Reprogramming of liver metabolism during West Nile virus infection unveils novel aspects of disease pathophysiology.
Mol Med. 2025 Jul 5;31(1):251. doi: 10.1186/s10020-025-01300-8.
3
Dehydrocostus lactone attenuates atherogenesis by promoting cholesterol efflux and inhibiting inflammation via TLR2/PPAR-γ/NF-κB signaling pathway.
Mol Med. 2025 Jun 19;31(1):243. doi: 10.1186/s10020-025-01265-8.
4
Hypomagnesemia: exploring its multifaceted health impacts and associations with blood pressure regulation and metabolic syndrome.
Diabetol Metab Syndr. 2025 Jun 16;17(1):217. doi: 10.1186/s13098-025-01772-y.
5
Oral microbiota signatures in obesity with or without acanthosis nigricans in a Chinese cohort.
J Med Microbiol. 2025 Jun;74(6). doi: 10.1099/jmm.0.002020.
6
Apolipoprotein M expression modifies the sphingolipid landscape in murine blood and lymph.
Front Immunol. 2025 May 2;16:1572959. doi: 10.3389/fimmu.2025.1572959. eCollection 2025.
7
Associations of APOE variants with sphingomyelin and cholesterol metabolites across the life-course in diverse populations.
Metabolomics. 2025 May 7;21(3):64. doi: 10.1007/s11306-025-02256-w.
8
The Associations of Maternal Prepregnancy Body Mass Index With Human Milk Fatty Acid and Phospholipid Composition in the Observational Norwegian Human Milk Study.
J Nutr. 2025 Jun;155(6):1818-1827. doi: 10.1016/j.tjnut.2025.04.009. Epub 2025 Apr 12.
9
Ceramide mediates cell-to-cell ER stress transmission by modulating membrane fluidity.
J Cell Biol. 2025 May 5;224(5). doi: 10.1083/jcb.202405060. Epub 2025 Mar 26.
10
Apolipoprotein and sphingolipid measurements: Can be used in the clinical practice of atrial fibrillation diagnosing and evaluating the cryoablation effectiveness?
PLoS One. 2025 Mar 4;20(3):e0315905. doi: 10.1371/journal.pone.0315905. eCollection 2025.
本文引用的文献
1
Targeting microsomal triglyceride transfer protein and lipoprotein assembly to treat homozygous familial hypercholesterolemia.
Crit Rev Clin Lab Sci. 2017 Jan;54(1):26-48. doi: 10.1080/10408363.2016.1221883. Epub 2016 Oct 1.
2
Sphingolipid De Novo Biosynthesis: A Rheostat of Cardiovascular Homeostasis.
Trends Endocrinol Metab. 2016 Nov;27(11):807-819. doi: 10.1016/j.tem.2016.07.005. Epub 2016 Aug 22.
3
Increase of gangliosides in atherosclerotic human aortas.
Lipids. 1975 Apr;10(4):256-9. doi: 10.1007/BF02532490.
4
Sphingomyelin is sorted at the trans Golgi network into a distinct class of secretory vesicle.
Proc Natl Acad Sci U S A. 2016 Jun 14;113(24):6677-82. doi: 10.1073/pnas.1602875113. Epub 2016 May 31.
5
Compounds of the sphingomyelin-ceramide-glycosphingolipid pathways as secondary messenger molecules: new targets for novel therapies for fatty liver disease and insulin resistance.
Am J Physiol Gastrointest Liver Physiol. 2016 Jun 1;310(11):G1102-17. doi: 10.1152/ajpgi.00095.2016. Epub 2016 May 12.
6
Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol.
Eur Heart J. 2016 Jul 1;37(25):1967-76. doi: 10.1093/eurheartj/ehw148. Epub 2016 Apr 28.
7
Sphingolipids in High Fat Diet and Obesity-Related Diseases.
Mediators Inflamm. 2015;2015:520618. doi: 10.1155/2015/520618. Epub 2015 Nov 16.
8
Defects of High-Density Lipoproteins in Coronary Artery Disease Caused by Low Sphingosine-1-Phosphate Content: Correction by Sphingosine-1-Phosphate-Loading.
J Am Coll Cardiol. 2015 Sep 29;66(13):1470-85. doi: 10.1016/j.jacc.2015.07.057.
9
Microsomal Triglyceride Transfer Protein Transfers and Determines Plasma Concentrations of Ceramide and Sphingomyelin but Not Glycosylceramide.
J Biol Chem. 2015 Oct 23;290(43):25863-75. doi: 10.1074/jbc.M115.659110. Epub 2015 Sep 8.
10
Sphingolipids in cardiovascular diseases and metabolic disorders.
Lipids Health Dis. 2015 Jun 16;14:55. doi: 10.1186/s12944-015-0053-y.
Zotero 插件